Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Two Indians are among 149 people aboard MV Hondius, the expedition cruise ship hit by a deadly hantavirus outbreak that has so far left three passengers dead and eight others infected, according to a BBC report.

The vessel, operated by Oceanwide Expeditions, began its journey from Ushuaia, Argentina, on April 1 and is currently travelling to Spain's Canary Islands on May 10.

According to the World Health Organization, eight people onboard the cruise ship MV Hondius have been infected with hantavirus. Of these, three have died, and five have been confirmed to have the virus. However, more people are likely to be infected, as the disease can take a long time to show symptoms.

The luxury cruise ship was carrying around 150 passengers and crew members from 28 countries.

The nationalities included 38 people from the Philippines, 31 from the United Kingdom, 23 from the United States, 16 from the Netherlands, 14 from Spain, nine from Germany, six from Canada and two crew members from India, BBC reported.

While it is yet not known whether they're infected or not, Dr Puneet Misra, Professor of Community Medicine, AIIMS Delhi, told ANI News Agency that it is likely that the two passengers "might have been exposed to the infection".

He added that "there is no pandemic or epidemic threat" with hantavirus. "The public should not worry. There is no need for panic..."

Follow this page for all latest updates:

US President Donald Trump is hopeful that the deadly hantavirus outbreak is very much under control. However, questions are mounting as his administration cut funding to study the rat-borne virus last year.

According to the World Health Organization, eight people onboard the cruise ship MV Hondius have been infected with hantavirus. Of these, three have died, and five have been confirmed to have the virus. However, more people are likely to be infected, as the disease can take a long time to show symptoms.

Speaking to reporters Thursday, Donald Trump sought to reassure Americans that the situation appeared contained.

“It’s very much, we hope, under control,” Trump said during an impromptu appearance near the Lincoln Memorial Reflecting Pool in Washington, DC. The President added that the administration planned to release “a full report” on the incident and said health officials were continuing to study the outbreak closely.

“We’re doing the best we can,” Trump told reporters when asked whether Americans should worry about the wider spread of the virus.

Notably, at least 23 passengers from the hantavirus-affected MV Hondius cruise ship returned home, including several to the United States — and one of them has already fallen ill.

Hantavirus Cases In The US?

The travelers reportedly did not know they had been exposed to the deadly virus when they disembarked during the ship’s stop at Saint Helena, a remote island in the South Atlantic, on April 23.

People in at least five US states — Georgia, Arizona, California, Texas, and Virginia — are reportedly being monitored for possible hantavirus exposure, though none have shown symptoms.

According to Dr. Jay Bhattacharya, Director of the US National Institutes of Health (NIH), “Hantavirus is not spread by people without symptoms, transmission requires close contact, and the risk to the American public is very low.”

CDC Cuts On Hantavirus Research

Behind the public reassurance, however, health authorities are confronting a situation that remains poorly understood — particularly because the Trump administration last year cut funding to study the virus behind the deadly cruise ship outbreak, and also fired scientists in key positions who were tracking viruses.

The Centers for Research in Emerging Infectious Diseases were designed to study viruses that could jump from animals to people, including hantavirus, but in 2025, the National Institutes of Health said the work would not continue.

Further, in its 2026 budget request, on one hand, the Trump administration said it planned to refocus the CDC on outbreak investigations and preparedness; on the other hand, it proposed eliminating about $750 million in preparedness grants that states rely on to cope with natural and man-made disasters, including outbreaks.

It also zeroed funding for the Hospital Preparedness Program, which strengthens healthcare systems to respond to emergencies, saying the program “has been wasteful and unfocused”, the New York Times reported.

Notably, the effects of the Trump administration’s cuts to infectious disease research are also being felt globally. South Africa has the capacity to sequence the hantavirus partly because of investments made by previous US administrations through the President’s Emergency Fund for AIDS Relief (PEPFAR), Dr. Carlos del Rio, an infectious disease expert at Emory University, told reporters.

However, the Trump administration has significantly reduced support for South Africa’s research system and is pulling back funding for PEPFAR.

“I worry that as we disinvest in global health, we’re losing our capacity — our global capacity — to deal with diseases,” Dr. Del Rio said.

The six-week-long incubation period of Hantavirus is a matter of concern, but the rat-borne disease is certainly not a large epidemic, said the World Health Organization today.

At a media briefing, the WHO Director General Dr Tedros Adhanom Ghebreyesus, expressed concerns about the time taken for the symptoms of the disease to appear.

He noted that so far the disease has been limited to the 150 people who traveled on board the MV Hondius ship. Of these, only 8 people have been infected - 3 have died, and 5 have been confirmed.

A case has been reported in a person who disembarked from the ship, without having the symptoms, and some have self-isolated to prevent the risk of spreading.

Among those on board the ship, now travelling to the Canary Islands, "currently no one is symptomatic".

However, "with a six-week incubation period, more cases are expected to be reported".

Countries involved in the contact tracing efforts of people who disembarked at St. Helena Islands include Canada, the Netherlands, Singapore, Turkey, the UK, and the US, the WHO chief said.

WHO infectious disease epidemiologist Maria Van Kerkhove reiterated that the disease spreads only among close, prolonged contacts or those providing care, as seen in the case of the doctor who got infected on board.

The WHO also noted that the disease is unlikely to become a large epidemic, as it's an isolated case occurring in a closed environment. However, public health measures like contact tracing and testing are key to preventing any further spread.

According to the WHO, the outbreak of the rat-borne disease among people aboard the MV Hondius ship after it left Argentina on April 1 was caused by the Andes strain.

Speaking to HealthandMe, Dr. Gautam Menon, Epidemiologist and Professor of Physics and Biology, Ashoka University, Delhi-NCR, said that the long incubation period is likely to complicate the spread of the hantavirus.

"What complicates matters is that incubation periods - the time between getting infected and symptoms showing - are large, up to several weeks, so passengers and their contacts will have to be quarantined for a long period before they can be declared safe." The expert said.

Is Hantavirus Similar To COVID-19?

Ven Kerkhove said that hantavirus causes severe respiratory issues, but it is still not the same as SARS-CoV-2.

This is not a new virus and is completely different from SARS-COV-2. It has caused similar outbreaks in Argentina in 2018, where contact tracing and other public health measures contained the spread.

"The outbreak of Hantavirus on a cruise ship has generated significant anxiety around the world, evoking memories of cruise ships affected by COVID-19 in the first phase of the pandemic. However, this is a different virus that is not known to spread efficiently from person to person. Its characteristics are already well-documented, unlike the SARS-CoV-2 virus, which was an unknown organism until then," Dr. Rajeev Jayadevan, Ex-President of IMA Cochin and Convener of the Research Cell, Kerala, told HealthandMe.

"The current cases do not indicate a pandemic threat, but they underline the growing importance of surveillance of zoonotic diseases. Strengthening rodent control, environmental hygiene, and early detection systems remains essential to prevent localized outbreaks and public panic. There is neither a proven treatment for its cure nor is there any vaccine," added Dr.Ishwar Gilada, Mumbai-based infectious disease expert.

How does The Hantavirus Affect The Human Body?

Hantavirus infection is caused by the hantavirus, which belongs to the Hantaviridae family. It is is rare but can be life-threatening.

The infection presents with initial symptoms resembling the flu and has a relatively high mortality of about 40%.

Also read: Hantavirus Sparks Global Alert As Countries Race To Trace Contacts; WHO Says Risk Low

Even though this virus is not believed to spread very efficiently, it would have done so far more easily in the enclosed environment that the ship provided, the experts said.

Dr Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, told HealthandMe that it can be contracted by coming into contact with rodent saliva, urine, and feces.

Hantavirus can cause infection - 2 syndromes: hantavirus pulmonary syndrome and haemorrhagic fever that may quickly develop into severe respiratory illness, as flu-like symptoms (fever, muscle aches, and fatigue) occur before developing serious respiratory symptoms (dyspnea) that may require respiratory assistance.

"On rare occasions, it can also spread from person to person through close contact. Rapid diagnosis and intensive medical treatment are critical for a successful outcome," Dr Rastogi said.

"Preventative measures include proper personal hygiene, avoiding contact with rodents or rodent-inhabited areas; using PPE when cleaning; and ensuring the area is well-ventilated," she added.

Although hantavirus infections can cause severe respiratory illness with high mortality, confirmed human cases globally remain relatively uncommon, Dr Gilada told HealthandMe

"The pneumonia syndrome caused by the virus is due to excessive permeability of blood vessels, resulting in fluid accumulation. It is managed with expert supportive care while the lungs recover, as there are currently no known antivirals or vaccines available for the Andes virus. By carefully tracking contacts and isolating those who might be infected, the virus can be stopped in its tracks, bringing this outbreak under control," Dr Jaydevan said.